Porges to Biogen: I don’t like your neuropathic pain drug; Ex-Moderna exec Bolen joins PureTech as CSO
Leerink’s Geoffrey Porges is pouring cold water over Biogen’s raxatrigine (BIIB074), a neuropathic pain drug it obtained in their $675 million deal to buy Convergence. Writes Porges: “We believe that Biogen’s neuropathic pain treatment candidate raxatrigine (BIIB074) faces long-odds due to the poor record of the class and troubling development history of this molecule; early signals are encouraging but at this stage we don’t see enough consistent evidence of benefit to add this to our model and value proposition for Biogen.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.